VERU vs. XERS, NATR, IVA, ATOS, PBYI, GALT, CAPR, OGI, OMER, and ZVRA
Should you be buying Veru stock or one of its competitors? The main competitors of Veru include Xeris Biopharma (XERS), Nature's Sunshine Products (NATR), Inventiva (IVA), Atossa Therapeutics (ATOS), Puma Biotechnology (PBYI), Galectin Therapeutics (GALT), Capricor Therapeutics (CAPR), Organigram (OGI), Omeros (OMER), and Zevra Therapeutics (ZVRA). These companies are all part of the "pharmaceutical preparations" industry.
Veru (NASDAQ:VERU) and Xeris Biopharma (NASDAQ:XERS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.
47.2% of Veru shares are owned by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are owned by institutional investors. 14.2% of Veru shares are owned by insiders. Comparatively, 4.6% of Xeris Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Veru currently has a consensus target price of $4.00, indicating a potential upside of 243.35%. Xeris Biopharma has a consensus target price of $4.63, indicating a potential upside of 140.26%. Given Veru's higher probable upside, equities research analysts clearly believe Veru is more favorable than Xeris Biopharma.
Xeris Biopharma has higher revenue and earnings than Veru. Xeris Biopharma is trading at a lower price-to-earnings ratio than Veru, indicating that it is currently the more affordable of the two stocks.
In the previous week, Veru had 10 more articles in the media than Xeris Biopharma. MarketBeat recorded 11 mentions for Veru and 1 mentions for Xeris Biopharma. Veru's average media sentiment score of 0.70 beat Xeris Biopharma's score of 0.00 indicating that Veru is being referred to more favorably in the media.
Veru received 130 more outperform votes than Xeris Biopharma when rated by MarketBeat users. However, 69.65% of users gave Xeris Biopharma an outperform vote while only 69.59% of users gave Veru an outperform vote.
Xeris Biopharma has a net margin of -37.58% compared to Veru's net margin of -265.27%. Veru's return on equity of -130.13% beat Xeris Biopharma's return on equity.
Veru has a beta of -0.47, indicating that its stock price is 147% less volatile than the S&P 500. Comparatively, Xeris Biopharma has a beta of 2.37, indicating that its stock price is 137% more volatile than the S&P 500.
Summary
Veru beats Xeris Biopharma on 10 of the 17 factors compared between the two stocks.
Get Veru News Delivered to You Automatically
Sign up to receive the latest news and ratings for VERU and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VERU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
